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peptide (SMRP)Abstract Background: Malignant mesothelioma (MM) carries a poor prognosis and response
rates to palliative chemotherapy remain low. The diagnosis of malignant mesothelioma is frequently
difﬁcult, the most common differential diagnosis being reactive pleural conditions and metastatic
adenocarcinoma. Several studies have used immunohistochemical markers to distinguish between
reactive and neoplastic mesothelial cells. Soluble mesothelin levels in serum have recently been
shown to be highly speciﬁc and moderately sensitive for mesothelioma. A combined detection of
serum levels of mesothelin and immunohistochemical expression of desmin and EMA are used in
order to differentiate between reactive mesothelial proliferations, and malignant mesothelioma of
epithelioid type.
Patients and methods: This prospective study includes 17 cases of reactive mesothelial prolifera-
tions, 6 cases of atypical mesothelial proliferations and 13 cases of MM. Cases were collected from
the Chest Department, Faculty of Medicine, Benha University and International Medical Center
(IMC), in the period 2012–2014. Desmin and epithelial membrane antigen (EMA) immunohisto-
chemical staining were performed in all cases and the pattern of expression was analyzed.
Soluble mesothelin related peptide (SMRP) was estimated for all cases.
Results: Desmin expression was positive in 88.2%, 0%, and 7.7% of reactive mesothelial prolif-
erations, atypical mesothelial proliferations and MM respectively. EMA was positive in 5.9% of
608 G.F. Al mehy et al.reactive mesothelial proliferation, 100% of atypical mesothelial proliferations and 92.3% of MM
cases (P< 0.01). The calculated mean SMRP was 6.6 nM. SMRP levels were higher than the cal-
culated mean value in 17.6% of studied reactive mesothelial lesions, 66.7% and 76.9% of atypical
mesothelial proliferations and MM respectively, which was statistically highly signiﬁcant correla-
tion (P< 0.01).
Conclusion: Combined estimation of SMRP level and immunohistochemical detection of both
EMA and desmin could be a useful tool for differentiation between reactive mesothelial prolifera-
tion and malignant mesothelioma.
ª 2015 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Malignant mesothelioma (MM) is an aggressive asbestos-
related cancer of serosal surfaces such as the pleura, peri-
toneum and rarely the pericardium. The cell of origin is a sub-
mesothelial mesenchymal stem cell. It is causally linked to
asbestos exposure [1]. According to the Egyptian National
Cancer Institute (NCI), MM constituted 13.12% of recorded
respiratory system tumors and 0.84% of total recorded malig-
nancy. The ratio between malignant lung tumors and pleural
mesothelioma was 1.8:1. Pleural mesothelioma showed a wide
age range starting from the 3rd to the 8th decade. However the
majority of the cases were between 30 and 70 years. Epithelioid
mesothelioma constituted 45.13% of all recorded mesothe-
liomas [2,3]. Diagnosis of MM is challenging as symptoms
and early radiographic signs are often non-speciﬁc and their
signiﬁcance can be masked by multiple co-morbidities of this
normally older patient. Malignant pleural mesothelioma has
a median survival of seven to ten months and a clinical pattern
that usually involves substantial pain and dyspnea. It presents
at a clinically advanced stage in most patients so there is a need
for new methods of early detection [4].
Mesothelial cells frequently show ﬂorid reactive changes in
response to many benign conditions such as pulmonary infarc-
tion, systemic disease (i.e., collagen-vascular diseases), cirrho-
sis, radiation, underlying neoplasm, chronic inﬂammation,
foreign substance, and infection. The distinction between
benign reactive mesothelial proliferations and malignant
mesothelioma (MM) may be very difﬁcult based only on histo-
logic and morphologic ﬁndings. Because of the difﬁculty in dis-
tinguishing reactive conditions from MM even in tissue
specimens, such as small pleural biopsies, several studies have
used immunohistochemical markers to distinguish between
reactive and neoplastic mesothelial cells [5].
The intermediate ﬁlament protein desmin is a known mar-
ker for smooth and skeletal muscle differentiation. Several
studies have reported positive staining of benign mesothelial
cells (reactive mesothelial proliferation) in serous ﬂuid and tis-
sue sections for desmin. The exact etiology for expression of
desmin in mesothelial cells is not known; however, the multi-
potential role of mesothelial cells with possible muscle differen-
tiation and coexpression of desmin has been proposed by some
studies [6,7].
Epithelial membrane antigen (EMA) is one of several gly-
coproteins found in human milk fat globule membranes. The
glycoprotein identiﬁed with EMA is known to be one of a ser-
ies of glycoproteins or mucins and is designated MUC1 [5]. It
is a high molecular weight transmembrane glycoproteinexpressed in cancer cells that suppresses cellular aggregation
and cell-matrix adhesion and promotes invasion of extracellu-
lar matrix by malignant cells. Moreover, it inhibits T-cell medi-
ated cytotoxicity through either induction of apoptosis in
activated T cells or inhibition of cytotoxic lymphocyte-target
cell interactions. MUC1 is also a ligand for ICAM-1
immunoglobulin which is expressed on endothelial cells. This
allows intravascular tumor cells to adhere to and invade
through the endothelial barrier; facilitating metastatic spread
[7,8].
Mesothelin is a 40 kDa membrane-localized protein that
along with the 31 kDa megakaryocyte potentiation factor
(MPF) are cleavage products of a 69 kDa precursor protein
encoded by MSLN gene on chromosome 16. In tissue culture,
Mesothelin is proposed to play a role in cell adhesion as it
binds to the cell adhesion molecule Ca125 (Muc16) and forced
over-expression of MSLN leads to increased adhesion to a
plastic substrate [9,10]. Also in tissue culture, mesothelin pro-
motes cell proliferation, invasion and apoptosis resistance.
Mesothelin may therefore be involved in cancer metastasis
and its role as a potential therapeutic target is being actively
pursued. It is predominantly expressed in epithelioid subtype
mesotheliomas, with little/no expression in sarcomatoid sub-
types. MPF and mesothelin isoforms 1 and 3 can be detected
as soluble proteins in plasma or serum, which may be detected
using a validated commercial dual antibody ELISA platform
[11,12].
The small amount of mesothelin shed into the serum could
make it a valuable diagnostic tool in cancers that express
mesothelin. It has been shown to potentially differentiate
between mesothelioma and other conditions, both benign
and malignant, and also potentially correlates with response
to therapy [1,13].
A study by Marchevsky [14] has demonstrated that the use
of many markers does not provide higher diagnostic accuracy
than the use of selected single antibodies or various combina-
tions of only 2 markers. In this work a combined detection of
serum levels of mesothelin and immunohistochemical expres-
sion of EMA and desmin are used in order to differentiate
between reactive mesothelial proliferations and malignant
mesothelioma of epithelioid type.
Patients and methods
This prospective study included 17 cases of non-neoplastic
reactive mesothelial proliferations, 6 cases of atypical mesothe-
lial proliferations and selected 13 cases of malignant mesothe-
lioma; epithelioid type. Thoracoscopic biopsies were collected
Figure 1 Reactive mesothelial proliferation showing relatively
bland monomorphic cuboidal cells with normal nuclear to cytoplas-
mic ratio (arrows). Few inﬂammatory cells are seen (H&E · 400).
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Benha University and the International Medical Center
(IMC) in the period (June 2012–June 2014). Parafﬁn-
embedded tissue sections were prepared from obtained biop-
sies. Hematoxylin and Eosin sections were reviewed by two
pathologists to conﬁrm diagnosis.
Immunohistochemical staining
Tissue sections were mounted on positively-charged slides,
steps of staining followed the standard ABC (avidin–biotin
complex) procedure using the Ultra Vision Detection System
(Anti-polyvalent, HRP/DAB, ready-to-use, Lab Vision corpo-
ration). Antigen retrieval was done with microwave treatment
in 10 mM citrate buffer (Neo-Markers, Cat. ] AP-9003), pH
6.0. Sections were incubated with rabbit monoclonal antibody
desmin (Lab Vision, Thermo scientiﬁc, USA, Cat. # RB-9014-
P0, 1:200 dilution) and with mouse monoclonal antibody
EMA (Lab Vision, Thermo scientiﬁc, USA, Cat. # MS-741-
P0, 1:200 dilution). The incubation and pretreatment time were
30 min at room temperature for both antibodies. The freshly
prepared DAB-substrate-chromogen solution was applied.
Immunostaining interpretation
Sections were evaluated under a light microscope and desmin
positivity was considered as brown cytoplasmic staining. The
results for desmin immunohistochemical stains were recorded
as negative when no immunoreactivity was seen, focal/weak
if <20% of cells were positive or showed only blush positivity,
and positive if strong positivity was seen inP20% of cells [6].
Only membranous staining was regarded as positive for
EMA. The results for EMA immunohistochemical staining
were recorded as negative (no staining), focal/weak if there
were a few (<20%) scattered cells that showed a membranous
staining pattern or if there was only blush cytoplasmic staining
but no membranous staining, and positive if there wereP20%
of mesothelial cells that showed strong membranous accentu-
ation and cytoplasmic staining [6].
Normal muscle tissue was taken as a control for positive
desmin expression and non-neoplastic breast tissue served as
a positive control for EMA. Negative controls were performed
by replacing the primary antibody with normal rabbit nonim-
mune IgG [6,8].
Mesothelin assay
The serum mesothelin assay was performed in a single labora-
tory. Serum samples were prospectively collected alongside
clinical data. Levels of serum mesothelin were assayed with a
commercial ELISA kit (Mesomark Fujirebio Diagnostics,
Malvern PA) according to the manufacturer’s instructions.
The MESOMARK assay was performed according to the
manufacturer’s instructions. Brieﬂy, patient serum samples
were diluted 1:101 using the assay diluent provided and
100 L of the diluted samples were added in duplicates to a
96-well plate precoated with the 4H3 antibody. The samples
were incubated on a plate-shaker for 60 min followed by a 5
rinse with wash buffer. The OV569-HRP conjugate was next
added to the sample wells and the microwell plate incubated
for a further 60 min on a plate-shaker. After a wash step,100 L of substrate was added to the reaction wells for 15 min
before adding 100 L of stop solution. The absorbance at
450 nm was used to quantify the soluble mesothelin-related
protein (SMRP) levels by comparison to a six-point calibration
curve. The MESOMARK values are expressed as nM
(nanomolar). Results were expressed in nanomoles per liter
(nmol/L). All analyses were performed in a batch, blinded to
clinical outcomes [15].
Statistical analysis
Data analysis was performed with the statistical package for
social sciences (version 16.0.1; SPSS Inc., Chicago, Illinois,
USA). Descriptive analysis of the variables and statistical sig-
niﬁcance of the tests were expressed in P-value. P value less
than 0.05 (<0.05) was considered signiﬁcant and <0.01 was
highly signiﬁcant.
Results
Histologically, reactive mesothelial proliferations were deﬁned
by relatively bland monomorphic cuboidal cells. These cells
have normal nuclear to cytoplasmic ratio, regular chromatin
pattern, with or without distinct nucleoli. Associated inﬂam-
matory reaction is sometimes present (Fig. 1).
The cells of atypical mesothelial proliferations are cuboidal
to elongate showing varying degrees of cytologic atypia with
enlarged nuclei, and often have prominent nucleoli with signif-
icant cell-to cell variation. In some cases atypical cells form a
single layer along the pleural surface, in other cases they tend
to form linear arrays between layers of ﬁbrin (Fig. 2).
Malignant mesothelioma cells show conspicuous malignant
cytologic features (severe pleomorphism, abnormal mitoses).
The tumor cells are arranged in solid nests or pseudoacini
and are surrounded by dense ﬁbrous tissue reaction. All cases
of MM included in this study were of epithelioid type with
invasion of underlying tissue (Fig. 3).
Immunohistochemical results
Fifteen cases (88.2%) of reactive mesothelial proliferations
were positive to desmin expression in the form of diffuse
Figure 2 Atypical mesothelial proliferation showing cuboidal to elongate showing varying degrees of cytologic atypia. (A) Atypical
mesothelial cells arranged on the pleural surface (thin arrow). (B) Atypical mesothelial cells tend to form linear arrays between layers of
ﬁbrin (thick arrow) (H&E · 400).
Figure 3 Malignant mesothelioma epithelioid type, showing malignant mesothelial cells arranged in pseudoacini and surrounded by
dense ﬁbrous tissue reaction. The cells show conspicuous malignant cytologic features (severe pleomorphism, marked hyperchromasia and
abnormal mitoses) (H&E · 400).
610 G.F. Al mehy et al.cytoplasmic staining (Fig. 4A). One case (16.7%) of atypical
mesothelial proliferations showed weak desmin expression
and one case (7.7%) of MM was positive to desmin immunos-
taining (Figs. 5A and 6A). There was a statistically highly
signiﬁcant inverse correlation (P< 0.01) between desmin
expression and type of lesion studied (Table 1).
Regarding EMA expression, one case (5.9%) of reactive
mesothelial proliferations was EMA positive (Fig. 4B). All
cases (100%) of atypical mesothelial proliferation and 12
(92.3%) cases of MM showed strong membranous accentua-
tion, with some cytoplasmic staining (Figs. 5B and 6B).
There was a statistically highly signiﬁcant correlation
(P< 0.01) between EMA expression and type of lesion stud-
ied (Table 1).
Cases were analyzed for combined immunoproﬁle of des-
min and EMA:Combination of Desmin +ve/EMA ve or Desmin
ve/EMA +ve could be used for differentiation between reac-
tive mesothelial proliferations and MM (P< 0.01), however,
atypical and malignant proliferations had the same immunopro-
ﬁle and could not be differentiated from each other (Table 2).
Serum mesothelin results
In the 36 patients tested for serum mesothelin the mean level
was 6.6 nM (range 0.3–102.5 nM). The value of 102.5 nM
appeared to be an outlier. The mean value was chosen a priori
and used for subsequent analyses.
The serum levels of mesothelin related protein were
P6.6 nM in 3 cases (17.6%) of reactive mesothelial prolifera-
tion, 4 cases (66.7%) of atypical mesothelial proliferation and
Figure 4 Reactive mesothelial cells showing (A) +ve cytoplasmic expression of desmin. (B) ve EMA expression (IHC, DAB · 400).
Figure 5 Atypical mesothelial proliferation showing (A) negative desmin expression (B). Positive EMA expression in the form of strong
membranous staining (IHC, DAB · 400).
Figure 6 Malignant mesothelioma showing (A) ve cytoplasmic desmin expression. Positive staining was detected in neighboring
muscle ﬁbers (B). Positive EMA in the form of strong membranous expression (IHC, DAB · 400).
Combined serum and immunohistochemical differentiation 61110 cases (76.9%) of mesothelioma. There was a statistically
highly signiﬁcant correlation (P< 0.01) between SMRP level
and type of studied cases (Table 3).
Discussion
Diagnosis of malignancy on pleural biopsy may be problem-
atic. Reactive pleural processes may be associated with pleural
effusion and thickening of the pleura and in some cases raise
the clinical possibility of malignancy, whereas some MMs
are cytologically bland or even indistinguishable from benignmesothelial cells or may be sampled in minimally invasive
areas that hide their malignant nature. It is of considerable
importance to patients to know that they have a benign pleural
process rather than MM [14,16]. Because cytologic atypia is
not a reliable factor [17], this work investigated a role of
immunohistochemical stains to make this distinction.
The current study found that diffuse cytoplasmic staining
of desmin was detected in 88.2% of reactive mesothelial prolif-
erations and 7.7% of MM cases. This was a statistically highly
signiﬁcant inverse correlation (P< 0.01). Parallel to such
results, Hasteh et al., [7] reported that desmin was positive in
Table 1 Expression of desmin and EMA among studied cases.
Total Desmin expression P value EMA expression P value
Negative Weak Positive Negative Weak Positive
Reactive mesothelial
proliferation
17 0 2 (11.8%) 15 (88.2%) P< 0.01 12 (70.6%) 4 (23.5%) 1 (5.9%) P< 0.01
Atypical mesothelial
proliferation
6 5 (83.3%) 1 (16.7%) 0 P< 0.01 0 0 6 (100%) P< 0.01
Mesothelioma 13 10 (76.9%) 2 (15.4%) 1 (7.7%) P< 0.01 0 1 (7.7%) 12 (92.3%) P< 0.01
Table 2 Combined immunoproﬁle of desmin and EMA in relation to type of examined cases.
Total Reactive mesothelial proliferation Atypical mesothelial proliferation Mesothelioma P value
Desmin +ve/EMA ve 12 12 (100%) 0 0 P< 0.01
Desmin +ve/EMA +ve 9 5 (55.6%) 1 (11.1%) 3 (33.3%) P> 0.05
Desmin ve/EMA ve 0 0 0 0
Desmin ve/EMA +ve 15 0 5 (33.3%) 10 (66.7%) P< 0.01
ve: negative, +ve: positive.
Table 3 Random soluble mesothelin-related protein levels.
Total SMRP level P value
<6.6 nM P6.6 nM
Reactive mesothelial
proliferation
17 14 (82.4%) 3 (17.6%) P< 0.01
Atypical mesothelial
proliferation
6 2 (33.3%) 4 (66.7%) P< 0.01
Mesothelioma 13 3 (23.1%) 10 (76.9%) P< 0.01
SMRP: Soluble mesothelin-related protein.
612 G.F. Al mehy et al.84% of cases of reactive mesothelial proliferation and in 6% of
MM cases (P< 0.01). Also Aﬁfy et al., [18] found that strong
cytoplasmic staining for desmin is observed in 92% of cases of
reactive mesothelial cells. In addition, Panjkoviu¨ et al., [19]
found that 100% of pleural MM is negative for desmin.
As desmin is considered a marker for smooth and skeletal
muscle differentiation, this work suggests loss of muscle differ-
entiation in MM cells. Desmin alone is not completely a reli-
able marker to differentiate between a reactive and a
malignant process in this study, because 7.7% of our MM
cases were positive, with an additional 15.4% focally positive.
It is possible that the focal desmin staining in the mesothe-
lioma cases represented a residual population of non-
neoplastic mesothelial cells [7].
In the current study, EMA expression was detected in 5.9%
of reactive mesothelial proliferations, while all cases (100%) of
atypical mesothelial proliferation and 92.3% of cases of MM
were EMA positive with strong membranous accentuation,
and some cytoplasmic staining. This was statistically highly
signiﬁcant (P< 0.01). These results were in agreement with
results reported by Hasteh et al., [7] who found that EMA
was positive in 9% of benign mesothelial proliferation and
100% of malignant mesothelioma cases (P< .001). Previous
studies have shown that strong staining for EMA is helpful
in excluding reactive mesothelial cells, although focal and
weak positivity has been reported [20].Shen, et al., [21] reported that EMA is most highly
expressed in epithelioid mesotheliomas and rarely in the sarco-
matoid subtype. Other reports, however, have shown that
reactive mesothelium can be positive for EMA in up to 70%
of cases [22]. Different antibody clones may account for these
conﬂicting results. Shen, et al., [21] also have conﬁrmed that
EMA is a speciﬁc marker of malignancy for mesothelioma
when staining is strong and diffuse. Minato et al., [23] reported
that EMA is a positive marker for MM which showed sensitiv-
ity of 79%, and speciﬁcity of 88%.
This study suggested that desmin and EMA not only serve
as markers for mesothelial cells in the appropriate setting, but
also their combination can aid in distinction between reactive
and malignant mesothelial cells. These results are matching
with results of Attanoos et al., [20] who concluded that desmin
and EMA appear to be the most useful markers in distinguish-
ing benign from malignant mesothelial proliferations. Desmin
appears to be preferentially expressed in reactive mesothelium
and EMA appears to be preferentially expressed in neoplastic
mesothelium. The complementary use of both markers is advo-
cated in ascertaining the nature of mesothelial proliferations.
Conversely, Salman et al., [24] found primary malignant
peritoneal mesothelioma with an unusual immunohistochemi-
cal proﬁle-desmin positive, EMA negative. In the study of
Minato et al., [23], they reported that in MM, the proportion
of positive tumor cells ranged from 5% to 100% (59%) for
EMA, and 5% for desmin. In reactive mesothelial lesions,
the proportion of positive mesothelial cells ranged from 5%
to 30% (mean, 12%) for desmin, 10% to 35% (19%) for
EMA.
These conﬂicting results might be attributed to differences
in patient populations, specimen types, scoring systems, and
anti bodies and antigen retrieval methods. The histologic sub-
types of MM included in each study may also affect the results.
In this study, SMRP levels were higher than the calculated
mean value (6.6 nM) in 17.6%, 66.7% and 76.9% of reactive
mesothelial proliferations, atypical mesothelial proliferations
and MM respectively, which was statistically highly signiﬁcant
correlation (P< 0.01). Parallel to such results Craeney et al.,
Combined serum and immunohistochemical differentiation 613[13] reported that signiﬁcantly higher levels of mesothelin were
found in effusions of patients with mesothelioma; with a speci-
ﬁcity of 98%, the assay had a sensitivity of 67% comparing
patients with mesothelioma and those with effusions of non-
neoplastic origin. Robinson et al., [25] reported in his study
on mesothelin family of proteins that patients with malignant
mesothelioma had a higher level of mesothelin related peptide
than the healthy control. Also Hollevoet et al., [26] reported
that in patients suspected of having mesothelioma, a positive
blood test for mesothelin at a high-speciﬁcity threshold is a
strong incentive to urge further diagnostic steps. Similarly
Hassan et al., [27] found that elevated serum mesothelin levels
were noted in 40 of 56 (71%) patients with mesothelioma. In
their meta-analysis study, Luo et al., [28] found that the esti-
mates for SMRPs in the diagnosis of malignant mesothelioma
in the studies included were sensitivity of 0.64 (95% conﬁdence
interval 0.61–0.68), speciﬁcity of 0.89 (0.88–0.90).
In conclusion combined estimation of SMRP level and
immunohistochemical detection of both EMA and desmin
could be a useful tool for differentiation between reactive
mesothelial proliferations and malignant mesothelioma of
epithelioid type. However atypical proliferations could not
be differentiated from MM in this work.
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